Evaluation of Intravenously Administered Tirapazamine Plus Cisplatin in Cervical Cancer, Phase II.

Closed

Phase

Accrual

100%

Published

Abbreviated Title

CERVICAL

Activated

08/15/1998

Closed

08/15/2000

Participants

NCORP, Members, Surgeons

Research committees

Gynecologic Cancer

Treatment

Cisplatin Tirapazamine

Eligibility Criteria Expand/Collapse

Hist. proven squamous or adenosquamous carcinoma of the cervix; advanced, metastatic or recurrent; not amenable to surgery or radiotherapy; measurable disease; no prior systemic therapy except for prior chemotherapy (including platinum agents) given in combination with radiotherapy; prior surgery OK; prior radiotherapy to < 30% of BM OK; no other concomitant chemotheapeutic agents, radiation therapy, or colony stimulating factor therapy may be planned; no allergy to mannitol.

Publication Information Expand/Collapse

2006

Tirapazamine plus cisplatin in advanced or recurrent carcinoma o fthe uterine cervix: a Southwest Oncology Group study

HO Smith;CS Jiang;GR Weiss;AV Hallum III;PY Liu;WR Robinson III;PC Cheng;SA Scudder;M Markman;DS Alberts Int Jrnl of Gyn Cancer 16:298-305

2004

Tirapazamine plus cisplatin in advanced or recurrent squamous or adenosquamous carcinoma of the uterine cervix: a phase II study of the Southwest Oncology Group

HO Smith;C Jiang;GR Weiss;AV Hallum;PY Liu;AM Miller;DR Gandara;M Markman;DS Alberts Gynecologic Oncology 92:416 (#49)